Bulletin

Investor Alert

Sorrento Therapeutics Inc.

NAS: SRNE

Set Alerts

Market Index

Overview Profile Charts Financials Historical Quotes Analyst Estimates Options SEC Filings Insiders

/marketstate/country/us

Sorrento Therapeutics Inc.

After Hours

SRNE

/zigman2/quotes/205669265/composite

1.03

Change

+0.02 +1.98%

Volume

Volume 6.06m

Jan 27, 2023, 7:59 p.m.

Quotes are delayed by 20 min

/zigman2/quotes/205669265/composite

Previous close

$ 0.96

$ 1.01

Change

+0.05 +5.21%

Day low

Day high

$0.96

$1.06

Open: 0.96

52 week low

52 week high

$0.74

$3.60

Market cap

$453.01M

Average volume

11.43M

P/E ratio

N/A

Rev. per Employee

$75,497

EPS

-1.33

Dividend

N/A

Div yield

N/A

Ex dividend date

N/A

Compare:

Indexes

Dow(INDU) INDU
Nasdaq (COMP) COMP
S&P 500 (SPX) SPX
Global Dow (GDOW) GDOW

/news/latest/company/us/srne

MarketWatch News on SRNE

Biotech Stocks Are Up by Double Digits. It's Still a Bear Market.

7:48 a.m. July 25, 2022

- Barron's Online
Sorrento Therapeutics' Covistix rapid tests outperforms in detecting omicron variant in initial lab tests

9:42 a.m. Dec. 27, 2021

- Tomi Kilgore
Sorrento Therapeutics says initial testing showed its COVISTIX test demonstrated ability to detect omicron variant

9:25 a.m. Dec. 27, 2021

- Tomi Kilgore
Sorrento Therapeutics triples number of its rapid COVID-19 tests distributed in Mexico

9:23 a.m. Dec. 27, 2021

- Tomi Kilgore
Sorrento Therapeutics started at buy with $26 stock price target at B. Riley

7:46 a.m. Jan. 29, 2021

- Tomi Kilgore
Charting market rotation, S&P 500 presses record territory

12:40 p.m. Jan. 26, 2021

- Michael Ashbaugh
Charting market rotation, S&P 500 presses record territory

12:16 p.m. Jan. 26, 2021

- Michael Ashbaugh
These are the non-pharma winners and losers from the Pfizer vaccine results

5:28 p.m. Nov. 10, 2020

- Michael Brush
Sorrento stock falls after company fires CFO

4:57 p.m. Aug. 18, 2020

- Wallace Witkowski
‘Clueless’ investors just keep driving this ‘stupidly bullish’ stock market higher, CNBC’s Jim Cramer says

12:01 p.m. Aug. 5, 2020

- Shawn Langlois
Sorrento Therapeutics, A Small Biotech, Licenses Quick Covid-19 Spit Test

7:01 a.m. July 29, 2020

- Barron's Online
Sorrento Therapeutics stock is a buy on the 50% chance of a COVID-19 antidote, analyst says

6:28 a.m. May 27, 2020

- Tomi Kilgore
Dow closes up 500 points, tests 25,000 level, on recovery hopes and vaccine news

3:42 p.m. May 26, 2020

- Joy Wiltermuth
Sorrento Therapeutics started at buy with $24 stock price target at Dawson James Securities

6:30 a.m. May 26, 2020

- Tomi Kilgore
America’s New Pastime: Day Trading

8:40 a.m. May 23, 2020

- Barron's Online
Sorrento stock's intraday high of $10 was nearly 4 times Thursday's closing price

1:39 p.m. May 18, 2020

- Tomi Kilgore
Sorrento Therapeutics' stock gains 1.9%, but pares earlier surge of as much as 48%

1:38 p.m. May 18, 2020

- Tomi Kilgore
Here’s what it will take for the stock market to hit a new record within 2 months

1:05 p.m. May 18, 2020

- Nigam Arora
Stocks Rise Because There Is ‘No Limit’ to What Fed Can Do

6:48 a.m. May 18, 2020

- Barron's Online
Sorrento Therapeutics' stock soars 44% premarket, after rocketing 158% on Friday

6:30 a.m. May 18, 2020

- Tomi Kilgore
Loading more headlines...

Analyst Ratings

Benzinga's Top Upgrades, Downgrades For August 4, 2017

8:37 a.m. Aug. 4, 2017

- Benzinga.com
Benzinga's Top Initiations

8:33 a.m. Oct. 3, 2016

- Benzinga.com
Benzinga's Top Initiations

10:01 a.m. Dec. 22, 2015

- Benzinga.com

/news/nonmarketwatch/company/us/srne

Other News on SRNE

Shares of newly public biotech Scilex climb 4% following SPAC merger (update)

4:20 p.m. Nov. 11, 2022

- Seeking Alpha
Sorrento: Limited Potential, High Management Compensation, Complicated Lawsuits

2:29 p.m. Nov. 9, 2022

- Seeking Alpha
ANI Pharmaceuticals (ANIP) Surpasses Q3 Earnings and Revenue Estimates

8:05 a.m. Nov. 9, 2022

- Zacks.com
Atara Biotherapeutics (ATRA) Reports Q3 Loss, Tops Revenue Estimates

5:15 p.m. Nov. 8, 2022

- Zacks.com
10-Q: SORRENTO THERAPEUTICS, INC.

4:34 p.m. Nov. 8, 2022

- Edgar Online - (EDG = 10Q, 10K)
Sorrento Therapeutics: Down The Rabbit Hole

11:34 p.m. Nov. 7, 2022

- Seeking Alpha
Catalyst watch: CPI downtick, election ripples, Disney and Rivian earnings, Roblox conference call

12:30 p.m. Nov. 4, 2022

- Seeking Alpha
Alnylam Pharmaceuticals (ALNY) Reports Q3 Loss, Misses Revenue Estimates

8:15 a.m. Oct. 27, 2022

- Zacks.com
Sorrento in credit agreement with B. Riley for $41.7M

2:36 p.m. Sept. 30, 2022

- Seeking Alpha
Morphic Holding, Inc. (MORF) Moves 7.3% Higher: Will This Strength Last?

9:15 a.m. Sept. 29, 2022

- Zacks.com
Sorrento Sofusa drug delivery system shows promise vs subcutaneous injection in trial

11:04 a.m. Sept. 15, 2022

- Seeking Alpha
Sorrento (SRNE) Gets FDA Fast Track Tag for Back Pain Product

11:45 a.m. Sept. 1, 2022

- Zacks.com
Why Sorrento Therapeutics Stock Is Marching Higher Today

11:01 a.m. Aug. 31, 2022

- Motley Fool
Hot Stocks: SRNE gains on FDA news, CHS rises on earnings, HPQ dips on Q3 estimates, and OSCR falls

7:16 a.m. Aug. 31, 2022

- Seeking Alpha
Sorrento stock rises 13% on FDA fast track status for low back pain therapy SP-103

3:40 a.m. Aug. 31, 2022

- Seeking Alpha
Sorrento (SRNE) Up on Positive Result From Lung Cancer Study

11:24 a.m. Aug. 24, 2022

- Zacks.com
2 Penny Stocks That Could Make You Filthy Rich

8:45 a.m. Aug. 24, 2022

- Motley Fool
Why Sorrento Therapeutics Stock Is Popping Today

2:08 p.m. Aug. 23, 2022

- Motley Fool
Sorrento achieves positive results in pivotal trial for abivertinib in NSCLC

9:45 a.m. Aug. 23, 2022

- Seeking Alpha
Sorrento Therapeutics: COVISTIX Sales Are Lagging Behind

1:21 a.m. Aug. 20, 2022

- Seeking Alpha
Loading more headlines...

/news/pressrelease/company/us/srne

Press Releases on SRNE

Sorrento Releases Positive Results from a Phase 1b Study in China in COVID-19 Patients and is Ready for Pivotal Phase 3 trials with OVYDSO(TM) (STI-1558), an Oral Mpro Inhibitor as a Standalone Treatment for COVID-19 without the Need for Ritonavir Boosting

9:00 a.m. Jan. 9, 2023

- GlobeNewswire
Sorrento Therapeutics has Received FDA Clearance to Initiate Clinical Trials with a Next Generation mRNA (STI-1557) Vaccine Against Omicron SARS-CoV-2 Virus

9:00 a.m. Dec. 6, 2022

- GlobeNewswire
Sorrento Announces Positive Phase II Results of PD-L1 Checkpoint Inhibitor IMC-001 Presented at Asian Congress of the European Society for Medical Oncology (ESMO)

3:01 p.m. Dec. 5, 2022

- GlobeNewswire
Sorrento Releases Positive Topline Results from the Phase I Study Completed in Australia and Preliminary Results from a Phase Ib Study in China with STI-1558, an Oral M(pro) Inhibitor as a Standalone Treatment for COVID-19 without the Need for Ritonavir Boosting

2:06 p.m. Nov. 29, 2022

- GlobeNewswire
Sorrento to Host Webcast to Discuss Newly Presented Clinical Data Demonstrating Significant Improvements in Therapeutic Outcomes in 10 of 10 Patients with Poorly Controlled Rheumatoid Arthritis

3:03 p.m. Nov. 13, 2022

- GlobeNewswire
Scilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento"), Debuts on Nasdaq Under Ticker "SCLX"

2:46 p.m. Nov. 10, 2022

- GlobeNewswire
Scilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento"), and Vickers Vantage Corp. I Announce the Closing of their Previously Announced Business Combination

2:15 p.m. Nov. 10, 2022

- GlobeNewswire
Scilex Holding Company ("Scilex"), a Sorrento Company (nearly 100% or over 99.9% majority-owned subsidiary of Sorrento Therapeutics, Inc.) (Nasdaq: SRNE, "Sorrento"), and Vickers Vantage Corp. I Announce Effectiveness of Registration Statement on Form S-4, Date of Vickers Vantage Extraordinary General Meeting to Approve Proposed Business Combination

8:01 a.m. Oct. 31, 2022

- GlobeNewswire
Nutriband Subsidiary, 4P Therapeutics LLC, Conducts Phase 1b Clinical Study for Sorrento Therapeutics, Inc. on Lymphatic Etanercept Delivery in Rheumatoid Arthritis Patients With Results To Be Presented at the 2022 American College of Rheumatology Conference

6:01 a.m. Oct. 26, 2022

- ACCESSWIRE
Why is Sorrento Therapeutics (SRNE Stock) Rising Today?

10:34 a.m. Oct. 21, 2022

- PressReach.com
Sorrento Successfully Completes Phase 1 Study and Is Proceeding to Implement Global Registrational Trials with STI-1558, an Oral Mpro Inhibitor as a Standalone Oral Treatment and Prevention of COVID-19 without the Need for a Ritonavir Booster

8:00 a.m. Oct. 17, 2022

- GlobeNewswire
Sorrento Announces Publication of Data in Cell Press Journal Med Describing Discovery and Preclinical Efficacy of a Broadly-Acting SARS-CoV-2 Neutralizing Antibody Administered IV (STI-9167) or IN (STI-9199)

1:57 p.m. Oct. 14, 2022

- GlobeNewswire
Sorrento Therapeutics to Participate in Key Opinion Leader Panel Discussion on "New Horizons for the Treatment of Non-small Cell Lung Cancer"

8:00 a.m. Oct. 6, 2022

- GlobeNewswire
Why Did SRNE Stock Drop 23.4% in September?

1:18 p.m. Oct. 5, 2022

- PressReach.com
Scilex Holding Company, a Sorrento Company, Announces Pre-Emptive Pay Off of Remaining Balance of its Senior Secured Notes

8:00 a.m. Sept. 29, 2022

- GlobeNewswire
Sorrento Therapeutics Completes Enrollment of Phase 2 Clinical Trial of Resiniferatoxin (RTX) for Treatment of Knee Pain in Moderate to Severe Osteoarthritis of the Knee (OAK) Patients

8:01 a.m. Sept. 26, 2022

- GlobeNewswire
Sorrento Stock Price Down 5.3%

10:30 a.m. Sept. 22, 2022

- PressReach.com
Sorrento Announces the Publication in the Nature Journal Scientific Reports the Details of the Discovery of SARS-CoV-2 Neutralizing Antibodies from the G-MAB Library

2:34 p.m. Sept. 15, 2022

- GlobeNewswire
Sorrento Reports Positive Trial Results Utilizing Sofusa Lymphatic Delivery of Etanercept, Achieving Significant Improvements in Rheumatoid Arthritis Disease Measures at 50% of the Standard Dose for Patients (7 of 7) with an Inadequate Response to Subcutaneous Injections

8:00 a.m. Sept. 15, 2022

- GlobeNewswire
Sorrento Therapeutics to Participate in Morgan Stanley 20th Annual Global Healthcare Conference September 12-14

8:00 a.m. Sept. 8, 2022

- GlobeNewswire
Loading more headlines...

Rates »

Mortgage Equity Savings Auto

National averages from Bankrate.com

MarketWatch.com

Follow MarketWatch
RSS
Podcasts

Intraday Data provided by FACTSET and subject to terms of use. Historical and current end-of-day data provided by FACTSET. All quotes are in local exchange time. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. Intraday data delayed at least 15 minutes or per exchange requirements.

Sorrento Therapeutics Inc.

MarketWatch News on SRNE

Analyst Ratings

Other News on SRNE

Press Releases on SRNE

Rates »

Latest News

dow

nasdaq

s&p 500

Kiosk